We reported previously that panaxydol, a component of Panax ginseng roots, induced mitochondria-mediated apoptosis preferentially in transformed cells. This study demonstrates that EGFR activation and the resulting ER stress mediate panaxydolinduced apoptosis, and that panaxydol suppresses in vivo tumor growth in syngeneic and xenogeneic mouse tumor models. In addition, we elucidated that CaMKII and TGF-b-activated kinase (TAK1) Ginsenoside and C17 polyacetylenic compounds of Panax ginseng (P. ginseng C.A. Meyer, Korean ginseng) roots possess anticancer activities. [1] [2] [3] [4] It has been shown that panaxydol (heptadeca-1-en-4,6-diyn-9,10-epoxy-3-ol), one of the C17 polyacetylenic compounds of P. ginseng, induces G1 cell cycle arrest or apoptosis in cancer cells depending on the concentration. 4, 5 We also previously reported that the mechanisms of panaxydol-induced apoptosis involve a rapid increase in the cytoplasmic Ca 21 concentration ([Ca 21 ]c), activating NADPH oxidase via p38/JNK. NADPH oxidase activation induces oxidative stress and triggers mitochondria-dependent apoptosis.
membrane (MAM), the site of local contact between the ER and mitochondria. 6, 7 Ca 21 that is released from the ER via inositol triphosphate receptors (IP 3 R) at the MAM generates microdomains with high Ca 21 concentrations at the contact sites. Ca 21 in these microdomains is then taken up by mitochondria through mitochondrial calcium uniporters (MCU). 7 However, the possibility is open that an increase in [Ca 21 ]c induces certain cellular events such as oxidative stress and ER stress that trigger mitochondrial Ca 21 uptake and apoptosis. ER stress is elicited by the accumulation of misfolded or unfolded proteins in the ER lumen, alterations in the ER Ca 21 store, oxidative stress and disturbances to the redox balance in the ER lumen. ER stress activates the unfolded protein response (UPR) in order to restore ER folding capacity 8, 9 ; however, if it overwhelms the UPR, apoptosis can be triggered either through a mitochondrial pathway or through direct activation of caspases. [10] [11] [12] [13] Recent research established the role of protein kinase R-like endoplasmic reticulum kinase (PERK), one of the key mediators of UPR, in ER stress-induced apoptosis. [14] [15] [16] PERK phosphorylates eukaryotic initiation factor-2 a (eIF2a), resulting in a reduction of global translation but enhancement of activating transcription factor 4 (ATF4) translation. ATF4 then activates expression of C/EBP homologous protein (CHOP, GADD153) which plays an important role in inducing both intrinsic and extrinsic apoptotic pathways. 13, [17] [18] [19] Here, we investigated the signaling mechanisms of panaxydol-induced apoptosis and elucidated the involvement of EGFR-PLCg, the CaMKII-TGF-b-activated kinase (TAK1)-p38/JNK pathway and ER stress in this process. In addition, panaxydol was shown to reduce tumor growth in vivo.
Material and Methods

Reagents and antibodies
MitoQ was a kind gift from Dr. Michael P. Murphy (Medical Research Council Dunn Human Nutrition Unit, UK). Apocynin, ruthenium red and PD153035 were purchased from Calbiochem (San Diego, CA), and N-acetyl cysteine (NAC), cisplatin and human recombinant tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) from Sigma (St. Louis, MO). Diphenyleneiodonium (DPI) and PP1 were obtained from Cayman Chemical (Ann Arbor, MI), and genistein was from Santa Cruz Biotechnology (Santa Cruz, CA). Salubrinal, phenylbutyric acid (PBA), W7, KN93, U73122, dantrolene and 2-aminoethoxydiphenyl borate (2-APB) were purchased from Tocris (Ellisville, MO). Fura-2 AM, fluo-4 AM and rhod-2 AM were from Molecular Probes (Eugene, OR).
Antibodies against BiP (sc-13968), CaMKII (sc-9035), CHOP (sc-7351), EGFR (SC-03), JNK (sc-571), p38 MAPK (sc-7972), TAK1 (sc-7967), p-CaMKII (sc-12886), p-eIF2a (SC293100) and p-ERK (SC7383) were purchased from Santa Cruz Biotechnology. Anti-p-EGFR (#4407S), anti-p-JNK (9255), anti-p-p38 (9211) and anti-caspase 7 (9491) antibodies were obtained from Cell Signaling (Danvers, MA), and anti-p-tyrosine antibody (#29808) was from Upstate Biotechnology (Lake Placid, NY). Antibodies against PLCg (LF-MA0049) and p-PLCg (Y783) (LF-PA20414) were purchased from Ab Frontier (Seoul, Korea).
Cell culture
MCF-7 human breast cancer, PC3 human prostate cancer and Renca mouse renal cancer cells were obtained from the Korean Cell Line Bank (Seoul, Korea) and maintained in RPMI 1640 or Dulbecco's modified Eagle's minimum essential medium (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum, 100 U/ml penicillin G sodium, 100 lg/ml streptomycin sulfate and 0.25 lg/ml amphotericin B.
Panaxydol preparation and treatment
Panaxydol was prepared from dried roots (white ginseng) of 6-year-old P. ginseng, certified by NongHyup Central Association (Korea), as described previously. 5 Briefly, the ginseng powder was extracted with petroleum ether (Mallinckrodt, Hazelwood, MO) at 408C in a shaking incubator. The extract was concentrated in a vacuum evaporator, loaded to a silicic acid (Merck, Daejeon, South Korea) column and eluted sequentially with 9:1, 8:2, 7:3 and 6:4 mixtures of petroleum ether and ethyl ether (Junsei, Tokyo, Japan). Fractions containing panaxydol were identified by silica gel thin layer chromatography, collected and stored at 2708C. Panaxydol was dissolved in dimethyl sulfoxide (DMSO) at 166 mg/ml and further diluted in the culture medium. The final concentration of DMSO in culture media did not exceed 0.1%.
Assessment of cytoplasmic and mitochondrial reactive oxygen species levels
Levels of cytoplasmic and mitochondrial reactive oxygen species (ROS) were estimated using the oxidation-sensitive fluorescent dye, 2,7-dichlorodihydrofluorescein diacetate (H 2 DCF-DA) (Invitrogen, Carlsbad, CA) and MitoSOX TM Red (Invitrogen), respectively. Cells were loaded with H 2 DCF-DA (100 nM) for 1 hr or MitoSOX Red (5 lM) for 30 min at 378C. After washing with phosphate-buffered saline What's new? Panax ginseng contains active compounds that may have anticancer properties. In this study, the authors found that the ginseng compound panaxydol is able to suppress tumor growth in mice. They also identified the complex molecular pathways by which this occurs, including EGFR activation, oxidative and endoplasmic-reticulum stress, calcium release, and the induction of apoptosis mediated by the mitochondria. These results indicate that panaxydol may be a promising therapeutic candidate.
(PBS), cells were treated with panaxydol, and ROS levels were analyzed using a flow cytometer (FACSCalibur TM , Becton Dickinson, San Jose, CA) or a fluorescence microscope (Eclipse 80i, Nikon, Tokyo, Japan).
Flow cytometry and fluorescence microscopy analysis of apoptosis
Apoptosis was analyzed by annexin-V-FITC and/or propidium iodide (PI) staining. Cells were cultured in the presence or absence of panaxydol and washed twice in cold PBS. Cells were then stained with annexin V-FITC (A13199, Invitrogen) and PI, according to the manufacturer's instructions. Briefly, annexin V-FITC (5 ll) was added to the cells in 100 ll binding buffer (10 mM HEPES, 140 mM NaCl and 2 mM CaCl 2 ; pH7.4). Cells were then incubated at room temperature for 15 min, and PI was added to the cells immediately before analysis by flow cytometry or fluorescence microscopy.
Ca 21 imaging
Analysis of intracellular free Ca 21 using digital imaging was performed by fura-2 (Molecular Probes) staining. When fura-2 binds Ca 21 , its maximal absorption wavelength shifts from 363 to 335 nm. Thus, MCF-7 cells (1 3 10 4 ) were cultured in 35-mm glass-bottomed dishes and loaded with fura-2 AM (2 lM) for 30 min at 378C. The fluorescence images of fura-2 were digitally captured at excitation wavelengths of 340 and 380 nm and at an emission wavelength of 510 nm, using an IX70 fluorescence microscope (Olympus, Tokyo, Japan) equipped with a digital cooled charge-coupled device (CCD) camera. Paired 340/380 ratio images were analyzed using Metafluor software (Molecular Devices, Sunnyvale, CA). Confocal images of intracellular and mitochondrial free Ca 21 were obtained using the Ca 21 -sensitive fluorescent dyes fluo-4 AM (Molecular Probes) and rhod-2 AM (Molecular Probes), respectively. Cells were loaded with fluo-4 AM (1 lM) or rhod-2 AM (1 lM) for 30 min at 378C, and Ca 21 imaging was carried out using a confocal laser scanning microscope (LSM510, Carl Zeiss, Jena, Germany).
siRNA transfection
Cells were transfected with siRNAs using Lipofectamine 2000 (Invitrogen) as described previously. 20 siRNAs were synthesized or purchased from Bioneer (Daejeon, Korea). The coding strand sequences of the siRNAs were as follows: 5 0 -CAG AGA ACU GUC UCG UAC UdTdT-3 0 (ATF6); 5 0 -CUG ACU ACC CUC UCA CUA GdTdT-3 0 (CHOP); 5 0 -GAU CCA CAG GAA CUG GAU A dTdT-3 0 (EGFR); 5 0 -AGA CUC UUC CAG CCC UAC UdTdT-3 0 (IRE1a); 5 0 -GAG AAC ACA GAA GAG UCU AdTdT-30 (PERK) and 5 0 -GUU CCC AAG GAG UGG CUU AdTdT-3 0 (TAK1). Experiments were performed 48 hr after siRNA transfection.
Analysis of the in vivo anticancer effects of panaxydol
Pathogen-free female BALB/c or BALB/c nu/nu mice were purchased from Orient Bio (Seoul, Korea) at 6 weeks of age and maintained in the standard animal facility. All animal experiments were approved by the Ethical Committee on Animal Research of the Korea University College of Medicine. Renca cells (5 3 10 5 ) in 200 ml of PBS were injected subcutaneously (s.c.) into the flank of BALB/c mice. For PC3 xenograft, 5 3 10 6 PC3 cells in 200 ml l3 PBS were inoculated s.c. into the flank of BALB/c nu/nu mice. After 7 days, three groups of four mice were intraperitoneally (i.p.) injected with different doses of panaxydol every 2 days for 3 weeks. A control group received an equal volume of PBS. Tumor volume was monitored by caliper measurement every 2 days and calculated using the standard ellipsoid formula: length 3 height 3 width 3 p/6.
Results
Panaxydol induces ER Ca 21 release by activating EGFR and PLCc
Panaxydol induced a rapid increase in [Ca 21 ]c, triggering an intracellular signaling cascade that resulted in apoptosis. 5 We initially examined whether the increase in [Ca 21 ]c was due to ER Ca 21 release. In MCF-7 cells, both 2-APB, an IP 3 R inhibitor, and dantrolene, a ryanodine receptor (RyR) inhibitor, blocked the panaxydol-induced increase in [Ca 21 ]c ( ]c (Fig. 1a) . PLCg activation was demonstrated 1 or 20 min after exposure to 50 or 20 lg/ml of panaxydol, respectively (Fig. 1b) . As an increase in [Ca 21 ]c triggered activation of NADPH oxidase and apoptosis as previously shown, 5 the effect of U73122 on panaxydol-induced cytoplasmic ROS generation and apoptosis was examined. As expected, U73122 blocked both cytoplasmic ROS generation and apoptosis ( Fig. 1c and Supporting Information Fig. S1 ). PLCg can be activated by receptor or nonreceptor tyrosine kinases. Therefore, the effects of several tyrosine kinase inhibitors on PLCg activation were investigated with the aim of identifying the upstream kinase pathway. A general tyrosine kinase inhibitor, genistein, and the EGFR inhibitors, PD153035, both prevented panaxydol-induced apoptosis in MCF-7 cells (Figs. 1d and 1e). It was shown that panaxydol-induced apoptosis could also be blocked in two different human non-small cell lung cancer cell lines, H460 and H1299 (Supporting Information Fig. S2 ). Panaxydol-induced apoptosis in HeLa cells was also blocked by PD153035 (Fig. 1e) . However, PP1 (a Src inhibitor), picropodophyllin (PPP; an IGF-1R inhibitor) and SU-6668 (an inhibitor of PDGFR, VEGFR and FGFR) did not affect panaxydol-induced apoptosis (Supporting Information Fig. S3 and data not shown). EGFR activation was observed as early as 1 min after panaxydol treatment (Fig.  1f) . Further supporting the role of EGFR, knocking down EGFR interfered with the increase in [Ca 21 ]c, cytoplasmic ROS generation and apoptosis ( Fig. 1g and Supporting Information Fig. S4 ). Taken together, these data strongly suggest that panaxydol activated EGFR-PLCg, triggering ER Ca 21 release and ROS generation through NADPH oxidase, thus leading to apoptosis. ]c results in activation of p38 and JNK, triggering NADPH oxidase activation. 5 Here, to study whether CaMKII played a role in activation of p38 and JNK, CaMKII activation was examined after panaxydol treatment. As shown in Figure 2a , CaMKII was activated within 5 min of exposure to 50 lg/ml panaxydol. CaMKII activation was dependent on ER Ca 21 release, as well as calmodulin, as pretreatment of cells with chemical inhibitors of PLCg (U73122), ER Ca 21 channels (4-APB and dantrolene) or calmodulin (W7) abolished CaMKII activation (Fig. 2b) . Furthermore, W7 or a CaMKII inhibitor (KN93) prevented panaxydol-induced ROS generation and apoptosis ( Fig. 2c and Supporting Information Fig. S5 ), indicating that calmodulin and CaMKII participate in the signaling pathway involved in panaxydol-induced apoptosis. As CaMKII can activate the mitogen-activated protein kinase kinase kinase (MAP3K), TGF-b-activated kinase (TAK1), [21] [22] [23] we investigated whether TAK1 mediated the activation of p38 and JNK through CaMKII. Indeed, panaxydol activated TAK1, as shown by TAK1 tyrosine phosphorylation (Fig. 2d) . Moreover, knockdown of TAK1 inhibited panaxydol-induced activation of p38 and JNK as well as apoptosis (Figs. 2e and  2f) . These results showed that calmodulin/CaMKII activated TAK1 to initiate the MAP kinase cascade that resulted in p38 and JNK activation. ]m) was assessed by rhod-2 staining. As shown in Figure 3a , [Ca 21 ]m increased 30 min after panaxydol treatment (50 lg/ml). The MCU inhibitor, ruthenium red, attenuated this increase in [Ca 21 ]m without affecting the elevation of [Ca 21 ]c (Fig. 3b) . Ruthenium red also blocked mitochondrial ROS generation, indicating that the increase in [Ca 21 ]m triggered mitochondrial ROS generation (Fig. 3c) ]m did not increase until 30 min (Fig. 3a) (a) MCF-7 cells were treated with 50 lg/ml panaxydol (P), and CaMKII activation was analyzed by immunoblotting using a p-CaMKII antibody at the times indicated after panaxydol treatment. Data shown are representative of more than three independent experiments. (b) Before panaxydol (P) treatment (50 lg/ml), cells were pretreated with U73122 (U, 10 lM), dantrolene (dan, 10 lM) or 2-APB (APB, 10 lM) (upper panel), or with W7 (10 lM) or KN93 (KN, 20 lM) (lower panel). CaMKII activation was analyzed 10 min after panaxydol treatment. Data shown are representative of more than three independent experiments. (c) MCF-7 cells were pretreated with KN93 (10 lM) or W7 (10 lM) for 1 hr. ROS generation was measured by H 2 DCF-DA staining after 15 min exposure to 50 lg/ml panaxydol. Data shown are representative of more than three independent experiments. (d) MCF-7 cells were treated with 20 or 50 lg/ml panaxydol (P20 or P50) and harvested at the indicated times. TAK1 was immunoprecipitated from wholecell lysates, and its activation was analyzed by immunoblotting of the immunoprecipitates using an anti-p-tyrosine antibody. Data shown are representative of more than three independent experiments. (e, f) MCF-7 cells were transfected with TAK1 siRNA. Forty-eight hours after transfection, TAK1 knockdown was assessed by immunoblotting. Cells were treated with panaxydol (50 lg/ml), and activation of ERK, p38 and JNK was assessed by immunoblotting after 5 min exposure to panaxydol (e). Apoptosis was analyzed by flow cytometry following annexin V and PI staining after 1 hr exposure to 50 lg/ml panaxydol (f). Data shown are representative of more than three independent experiments. other events. In fact, ROS generation by NADPH oxidase, which occurred 10-15 min after panaxydol treatment, 5 To address the molecular mechanism linking cytoplasmic oxidative stress and elevated [Ca 21 ]m, we evaluated whether ER stress was involved. Initially, ER stress markers were analyzed in MCF-7 cells treated with 20 lg/ml panaxydol. As shown in Figure 4a , phosphorylation of eIF-2a and expression of CHOP and BiP increased from 2 to 4 hr after exposure to panaxydol. Induction of CHOP and Bip protein expression was prevented by the ER stress inhibitors, salubrinal and PBA (Supporting Information Fig. S6 ). We then examined whether elevated [Ca 21 ]c and the resulting oxidative stress caused ER stress. The ROS scavenger, NAC, as well as inhibitors of Ca 21 signaling such as BAPTA-AM and W7, abolished the induction of CHOP expression (Fig. 4c) . However, neither the mitochondrial antioxidant, mitoQ, nor the MCU inhibitor, ruthenium red, reversed the induction of CHOP expression (Fig. 4c) . Thus, while oxidative stress caused ER stress after panaxydol treatment, mitochondrial ROS generation or Ca 21 uptake was not involved in the induction of ER stress. Indeed, ER stress mediated panaxydol-induced apoptosis, as PBA and salubrinal abrogated this effect (Fig. 4b) . Together, these data suggest that panaxydol-induced cytoplasmic oxidative stress caused ER stress, thereby mediating an increase in [Ca 21 ]m, subsequent mitochondrial ROS generation and apoptosis.
PERK, CHOP and bim mediate ER stress-induced apoptosis by panaxydol
To evaluate the contribution of the UPR signal branches of ER stress in panaxydol-induced apoptosis, PERK, IRE1a or ATF6 was knocked down by RNA interference. While PERK knockdown completely inhibited panaxydol-induced apoptosis, knockdown of IRE1a or ATF6 did not exert any significant effect (Fig. 4d) . Silencing of PERK, IRE1a or ATF6 expression by specific siRNA transfection was confirmed (Supporting Information Fig. S7 ). These results suggested that PERK, but not IRE1 or ATF6, transmitted the apoptosis signal from the ER to mitochondria. PERK is known to induce CHOP through eIF2a and ATF4, and CHOP activates transcription of proapoptotic genes such as Bim and Puma, conveying the apoptotic signal to the mitochondria. 25, 26 Consistent with this notion, silencing CHOP blocked the increase in [Ca 21 ]m without affecting that of [Ca 21 ]c (Fig. 4e) , and prevented apoptosis (Supporting Information Fig. S8 ). The mRNA level of Bim was enhanced after panaxydol treatment, and this increase was abrogated by CHOP knockdown (Fig.  1f) . Silencing Bim suppressed panaxydol-induced apoptosis (Supporting Information Fig. S9a) , confirming the role of this molecule in apoptosis induction. Although the mRNA expression of Puma was also increased by panaxydol, Puma silencing did not prevent panaxydol-induced apoptosis (Supporting Information Fig. S9b ). It has been reported that ER stress triggered by several ER stress inducers upregulates the protein expression of Bim but not that of Puma in MCF-7 cells. 17 Together, these data indicate that PERK, CHOP and Bim sequentially transmit the panaxydol-induced apoptosis signal from the ER to mitochondria.
Panaxydol synergizes the cytotoxic effect of cisplatin and reduces in vivo tumor growth
The synergistic effect of panaxydol and two other anticancer agents, cisplatin and TRAIL, on the induction of cell death was investigated in MCF-7 cells. Cisplatin is widely used as a chemotherapeutic drug and is known to induce oxidative stress, 27 whereas TRAIL induces apoptosis selectively in cancer cells through a death receptor pathway. As shown in Figure 5a , panaxydol and cisplatin synergistically induced cell death in MCF-7 cells, suggesting the possibility of combination therapy. ER stress is known to induce the expression of death receptor 5 (DR5), and panaxydol increased mRNA expression of DR5 (Fig. 4f) . However, TRAIL alone did not induce apoptosis in MCF-7 cells, and no synergistic or additive effects were found when cells were co-treated with panaxydol and TRAIL (Fig. 5b) , indicating that a death receptor pathway did not contribute to panaxydol-induced apoptosis.
In vivo tumor growth was also reduced by panaxydol. Mouse renal cell carcinoma Renca cells were inoculated into syngeneic BALB/c mice 1 week before initiating 3-week panaxydol therapy (100 or 200 mg/kg every 2 days). Administration of 100 or 200 mg/kg panaxydol reduced the tumor size dose-dependently, demonstrating that panaxydol exerts an anticancer effect in vivo (Figs. 5c and 5d ). Inhibition of in vivo tumor growth was also demonstrated with a PC3 human prostate cancer xenograft. PC3 cells were inoculated in BALB/c nude mice 1 week before the initiation of 3-week panaxydol therapy (50 or 100 mg/kg every 2 days). As shown in Figure 5e and Supporting Information Fig. S10 , panaxydol inhibited growth of the PC3 xenograft dose-dependently, with complete suppression at 100 mg/kg.
Discussion
In this study, we showed that EGFR activation and ER stress mediate panaxydol-induced apoptosis. EGFR and PLCg were activated within 1 min of exposure to 50 lg/ml panaxydol in MCF-7 cells. A lower concentration of panaxydol (20 lg/ml) appeared to induce the same signaling events with slower kinetics. Pretreating cells with an EGFR inhibitor (PD153035) or silencing EGFR expression prevented an increase in [Ca 21 ]c, ROS generation and apoptosis, indicating that EGFR indeed initiates the apoptosis-inducing signaling pathway. Although extensive evidence indicates that EGFR activation confers resistance to cytotoxic drugs and anticancer agents, [28] [29] [30] there are also a few reports showing that EGFR activation can induce cell death and/or ER stress. [31] [32] [33] [34] [35] Considering that EGFR is activated in many types of cancer and affords protection from chemotherapeutic drugs, it is intriguing that panaxydol induces apoptosis through EGFR activation.
As we reported previously, ER Ca 21 release and the resulting increase in [Ca 21 ]c activated p38 and JNK, leading to NADPH oxidase activation. This study identified that CaMKII and the MAP3K, TAK1, mediated calcium-induced activation of p38 and JNK. CaMKII has been shown to directly bind and activate TAK1. 23 release may induce ER stress directly, our results suggest that it can also do so indirectly via NADPH oxidase activation and the subsequent oxidative stress. In this study, ER stress mediated panaxydol-induced mitochondrial apoptosis. Among the three major UPR branches, PERK and IRE1a are known to mediate apoptosis induced by ER stress. 11, 13, 38, 39 We found that PERK, but not IRE1a or ATF6, played a role in panaxydol-induced apoptosis. PERK performs a dual role in the delivery of apoptotic signals from the ER to the mitochondria. 17, 40 First, it induces a proapoptotic transcription factor, CHOP, via canonical PERK-eIF2a-ATF4 signaling; second, PERK localized in MAM is required for tethering ER to mitochondria in a kinase activity-independent manner. In the first scenario, Bim and Puma, the proapoptotic transcriptional targets of CHOP, are known to play an important role in ER stress-triggered apoptosis. 17, 25, 26 In panaxydol-induced apoptosis, CHOP-dependent Bim upregulation was observed, and silencing PERK, CHOP or Bim abrogated panaxydol-induced apoptosis, suggesting that the PERK-CHOP-Bim axis transmitted the apoptosis signal from the ER to the mitochondria.
An in vivo anticancer effect of panaxydol was identified in mouse tumor models using mouse renal carcinoma (Renca) and human prostate cancer (PC3) cells. Panaxydol administration, started 7 days after tumor cell inoculation, significantly reduced the growth of both Renca and PC3 tumors. In addition, combined treatment with panaxydol and cisplatin exhibited a synergistic cytotoxic effect in vitro, raising a possibility of combination therapy. Although expression of DR5 can be induced by CHOP, and the death receptor pathway contributes to ER stress-induced apoptosis, 41, 42 TRAIL and panaxydol treatment did not produce a synergistic effect in MCF-7 cells. In conclusion, this study, together with our previous report, elucidates the detailed molecular mechanisms involved in panaxydol-induced apoptosis (Fig. 6 ) and demonstrated the in vivo anticancer activity of panaxydol, suggesting it as a promising anticancer candidate. 
